CuraGen, TopoTarget initiate ovarian cancer trial
15th Nov 2006, 05:02 GMT
CuraGen Corporation and TopoTarget have initiated patient dosing in a phase II trial evaluating the antitumor activity of PXD101 in the treatment of ovarian cancer.
CuraGen, TopoTarget initiate ovarian cancer trial related news:
- CuraGen and TopoTarget Announce Initiation of NCI-Sponsored Phase II Trial of PXD101 for Ovarian Cancer — PR Newswire: All Releases
- New drug comb may lengthen ovarian cancer survival — Reuters: Health
- Babies still an option for those with ovarian cancer? — Blogging Baby
- Other highlights in the November 15 JNCI — EurekAlert! - Biology
- Ovarian Cancer Studies Elusive: Should Erlotinib Be Added to Chemotherapy? — Medscape Hematology-Oncology Headlines
- Executive Q&A: Sara Sinaiko - Helping heal those touched by cancer — madison.com - RSS
- Scientists Design A PSA-activated Protoxin That Kills Prostate Cancer: Phase I Clinical Trial Is Under Way — Health News from Medical News Today
- Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up — Prostate Cancer and Prostatic Diseases
- 'Johanna's Law' Passed in the House of Representatives; New Bill Will Save Thousands of Women's Lives — ArriveNet : Press Releases
- Recurrent breast cancer: Drug shows promise — The Cancer Blog
Latest news from Pharmaceutical Business Review Latest News:
- Celesio revenues, profits up
- Amgen arthritis drug shows sustained safety and efficacy
- Study supports cardiovascular safety of naproxen
- Cangene chickenpox drug granted orphan status
- Reata brain cancer therapy shows strong activity
- Novartis diabetes drug faces three month delay
- Favrille drug fails secondary goal
- Neurogen commences human testing of obesity drug
- Aeterna prostate cancer drug shows promise
- Isis says new drug effective against cholesterol